Study guide
8.6 Lactation Complications, Medication Safety & Contraindications
AMCB Certified Nurse-Midwife CNM
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care
1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral
2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts
2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy
3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy
3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy
4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss
4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care
5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance
5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion
6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation
6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy
7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair
7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture
8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation
8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications
9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage
9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation
10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health
10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis
11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination
11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes
12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days
12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days
13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization
13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening
14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation
14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral
15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders
15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome
16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause
16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis
17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions
17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking
18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity
18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care
8.6 Lactation Complications, Medication Safety & Contraindications
Key Takeaways Explain This Topic AI
Mastitis is unilateral with wedge-shaped erythema and fever of 38.3 degrees Celsius or higher, while engorgement is bilateral, diffuse, and afebrile or minimally febrile.
Reverse pressure softening applies steady fingertip pressure at the areolar base toward the chest wall for 60 seconds to displace edema and restore a latchable areola.
A relative infant dose below 10 percent is generally considered safe, and drugs above 90 percent protein-bound or above 800 to 1,000 daltons transfer minimally.
HTLV-I and HTLV-II infection, classic galactosemia, active untreated brucellosis, and cytotoxic chemotherapy or radioactive isotopes remain absolute contraindications to breastfeeding.
US guidance since 2023 treats HIV as a shared decision, not an absolute contraindication: replacement feeding carries zero risk while breastfeeding on suppressive therapy carries under 1 percent risk, and breastfeeding stops if viral load becomes detectable.
Last updated: September 2026
Differential Diagnosis & Midwifery Management of Lactation Complications
Condition Onset & Clinical Features Physical Examination Findings Systemic Symptoms Primary Midwifery Management
Sore / Cracked Nipples Days 1–7; sharp pain with initial latch lasting through feed Erythema, fissures, cracks, blisters, or lipstick-shaped flattening None (afebrile) Observe full feeding; correct latch to deep asymmetric placement; apply expressed breast milk or medical-grade lanolin; air dry; hydrogel pads.
Pathologic Engorgement Days 2–5; bilateral severe throbbing breast ache and fullness Bilateral diffuse swelling; breasts firm, warm, taut, shiny; areola stiff/flat Low-grade fever (<38.0°C) may occur ("milk fever") Reverse pressure softening (RPS) to soften areola; brief hand expression before latch; cold packs between feeds; scheduled oral ibuprofen 600–800 mg q6h.
Plugged Milk Duct Gradual; localized focal tenderness and palpable lump Discrete, localized, tender nodule in one lobe; no overlying redness or mild erythema Afebrile; no systemic flu-like symptoms Frequent nursing; position infant chin toward nodule; warm moist heat and massage toward nipple; oral lecithin 1,200 mg PO 3–4x daily.
Acute Infective Mastitis Sudden onset (often weeks 2–6); intense localized pain Unilateral wedge-shaped erythema, induration, and intense heat High fever (≥38.3°C / 101°F), shaking chills, flu-like myalgias Empty breast completely (continue nursing/pumping); oral dicloxacillin or cephalexin 500 mg QID x 10–14 days; analgesia; fluids; rest.
Mammary Candidiasis (Thrush) Weeks to months postpartum; burning, stabbing, shooting pain radiating into chest wall Nipples shiny, flaky, deep pink; fine fissures; infant may have oral thrush or diaper dermatitis Afebrile; maternal pain out of proportion to exam Simultaneous dyadic treatment: infant oral nystatin; maternal topical miconazole/clotrimazole 2% cream; oral fluconazole for deep ductal symptoms; boil pump parts.
Clinical Deep-Dive: Reverse Pressure Softening (RPS)
Pathologic engorgement causes severe interstitial fluid accumulation in the areola, flattening the nipple and making it physically impossible for the infant to latch deeply, resulting in severe nipple trauma and milk stasis.
RPS Technique: Instruct the mother to place the curved tips of her fingers (or the sides of two thumbs) at the base of the nipple around the areolar ring, pressing steadily and firmly inward toward the chest wall for 60 seconds . This gentle pressure temporarily displaces interstitial lymphatic edema backward and inward into deeper breast tissue, creating a compliant, soft 1-inch ring around the areola that allows the infant to achieve a deep, pain-free latch.
- Medication Safety & Contraindications During Lactation
- Pharmacokinetics of Drug Transfer into Breast Milk
Most medications enter human breast milk via simple passive diffusion across the capillary endothelium and the alveolar epithelial membrane. The extent of maternal drug transfer depends on distinct physicochemical characteristics:
Protein Binding: Drugs with high maternal plasma protein binding (>90%) (e.g., ibuprofen, warfarin) have very little unbound, free drug available to diffuse into milk.
Molecular Weight: High molecular weight compounds ( >800 to 1,000 Daltons ) (e.g., heparin, insulin, infliximab) are too large to traverse alveolar membrane pores.
Lipid Solubility: Highly lipophilic compounds penetrate the alveolar cell lipid bilayer more readily, achieving higher concentrations in hindmilk.
Relative Infant Dose (RID): The most accurate, clinically useful parameter for assessing infant drug exposure: RID = Infant Dose via Milk (mg/kg/day) Maternal Dose (mg/kg/day) × 100 \text{RID} = \frac{\text{Infant Dose via Milk (mg/kg/day)}}{\text{Maternal Dose (mg/kg/day)}} \times 100 RID = Maternal Dose (mg/kg/day) Infant Dose via Milk (mg/kg/day) × 100
RID <10%: Widely accepted by clinical pharmacologists as clinically safe for full-term, healthy infants.
RID <1%: Negligible infant exposure (ideal).
Hale's Lactation Risk Categories
L1 (Safest): Controlled studies in lactating women fail to demonstrate infant risk (e.g., acetaminophen, ibuprofen, cephalexin, penicillin, labetalol).
L2 (Safer): Studied in a limited number of women with no increase in adverse effects (e.g., sertraline, amoxicillin-clavulanate, nifedipine, prednisone).
L3 (Moderately Safe): No controlled studies exist, or controlled trials show minimal, mild adverse effects (e.g., fluconazole, ciprofloxacin, quetiapine).
L4 (Possibly Hazardous): Positive evidence of infant risk, but maternal health benefits may justify use in life-threatening scenarios.
L5 (Hazardous / Contraindicated): Significant, documented risk to the infant; strictly contraindicated during lactation (e.g., methotrexate, cyclophosphamide, radioactive isotopes, illicit drugs).
Absolute Medical Contraindications to Breastfeeding
In high-resource settings such as the United States (per AAP, ACOG, and CDC guidelines), breastfeeding is strictly contraindicated in the presence of:
Maternal HIV infection: In high-resource settings where safe, clean, affordable replacement infant formula is universally available, maternal HIV is a contraindication to breastfeeding due to the risk of vertical transmission. (Note: In low-resource global settings, WHO recommends exclusive breastfeeding with maternal antiretroviral therapy).
Human T-cell Lymphotropic Virus (HTLV-I / HTLV-II).
Active, untreated brucellosis.
Active, untreated pulmonary tuberculosis: The infant should be temporarily separated from the mother until she has received anti-TB chemotherapy for ≥2 weeks and is documented as non-contagious. Crucially, expressed breast milk may be fed to the infant by an unaffected caregiver , as Mycobacterium tuberculosis is not transmitted via milk.
Active herpes simplex virus (HSV) lesions on the breast or nipple: Breastfeeding is contraindicated from the affected breast until all lesions are completely crusted and healed. The infant may nurse from the unaffected contralateral breast if all lesions on the affected side are completely covered.
Active Ebola or Marburg virus disease.
Maternal cytotoxic chemotherapy or diagnostic/therapeutic radioactive isotopes (e.g., iodine-131, which concentrates in breast milk and damages the neonatal thyroid gland).
Maternal illicit drug use: Active use of cocaine, methamphetamine, phencyclidine (PCP), or non-prescribed opioids. Crucial Exception: Mothers maintained on stable, supervised medication-assisted treatment (MAT) for opioid use disorder with methadone or buprenorphine should be strongly encouraged to breastfeed , as minimal drug transfers into milk, and breastfeeding significantly reduces the severity of Neonatal Opioid Withdrawal Syndrome (NOWS).
Infant Metabolic Disorder: Classic galactosemia (absence of galactose-1-phosphate uridylyltransferase) is an absolute infant contraindication to human milk, requiring galactose-free soy formula. (Note: Infants with phenylketonuria [PKU] can successfully receive measured amounts of human milk paired with phenylalanine-free metabolic formula under specialty supervision).
Update: HIV and Infant Feeding in the United States
The blanket listing of maternal HIV as an absolute contraindication reflects older guidance and has been superseded . Since 2023, the US Department of Health and Human Services perinatal guidelines and ACOG have moved to a shared decision-making model :
Replacement feeding with formula or pasteurized donor human milk eliminates postnatal HIV transmission risk entirely and remains the option that carries zero risk.
For a patient on antiretroviral therapy with a sustained undetectable viral load through pregnancy and postpartum, the risk of transmission through breastfeeding is less than 1%, but not zero .
Clinicians should counsel privately, non-judgmentally, and with evidence — exploring the patient's motivations for breastfeeding and any barriers to formula feeding — and then support the patient's informed choice .
If the viral load becomes detectable (≥50 copies/mL) while breastfeeding, breastfeeding is stopped immediately and replacement feeding begins.
Punitive or coercive responses to a patient's decision to breastfeed are explicitly discouraged; the appropriate response is intensified viral-load monitoring and infant prophylaxis per current perinatal guidelines.
On an exam question that asks for an absolute contraindication, HTLV-I/II, classic galactosemia, active untreated brucellosis, and cytotoxic chemotherapy or radioactive isotopes remain unambiguous choices , while HIV now requires this nuanced answer.